Abstract
BackgroundTo enhance the convenience and reduce the cost of prostate cancer (PC) screening, a one-step prostate-specific antigen (PSA) test was evaluated in a large population. The PSA SPOT test kit enables rapid detection of human PSA in serum or plasma at or above a cutoff level of 4 ng/mL to aid in the diagnosis of PC.MethodsPC screening using the PSA SPOT test was offered to male participants in educational public lectures that we conducted in various cities. Test results were reported to participants at the end of the lectures. Blood samples from 1429 men were evaluated. Two independent observers interpreted the tests at 15 and 30 min. The remaining serum samples were subsequently tested using a conventional quantitative assay.ResultsThe sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the test were 79.9, 93.0, 65.4, 96.6, and 91.2%, respectively. The sensitivity and specificity of the test changed with variations in the reading time. Quantitative assessment of the intensity of the band was correlated with the PSA value.ConclusionsPSA testing using this kit can be easily performed. The low cost and speed of the test make it a useful and convenient tool for primary PC screening.
Highlights
To enhance the convenience and reduce the cost of prostate cancer (PC) screening, a one-step prostate-specific antigen (PSA) test was evaluated in a large population
PC screening is still controversial, as the potential benefits and harms continue to be debated among health professionals
Another issue involves the economics of PC screening, including the costs associated with detection, treatment, and treatment-related complications
Summary
To enhance the convenience and reduce the cost of prostate cancer (PC) screening, a one-step prostate-specific antigen (PSA) test was evaluated in a large population. The widespread use of the prostate-specific antigen (PSA) test is thought to be responsible for the rapid increase in PC diagnoses between 1988 and 1992 in the United States [2, 3]. Both the high prevalence of PC and availability of PSA tests capable of detecting PC at an early stage are important criteria required to support mass screening. Some patients might suffer from complications associated with the treatment of clinically insignificant PCs that would probably never lead to death Another issue involves the economics of PC screening, including the costs associated with detection, treatment, and treatment-related complications. Optenberg and Thompson estimated that the cost of screening could be as high as $25 billion annually if all men Ashida et al BMC Urol (2021) 21:135
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
